GlassScriptPhysician profile
Revathi Angitapalli
NPI 1497921829
$18,888.58
in general payments reported to CMS, 2019-2025
85 companies · $4,276 in 2025
The $4,276 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,563 · 2020: $4,010 · 2021: $486 · 2022: $597 · 2023: $2,175 · 2024: $3,781 · 2025: $4,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,121 · Long Term Medical Supply Or Device Loan: $1,995 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,120.74 |
| Long Term Medical Supply Or Device Loan | $1,995.48 |
| Education | $116.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,084.68 | 2019-2025 | |
| Roche Products Limited | $2,213.79 | 2020 | |
| Celgene Corporation | $899.33 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $856.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $692.54 | 2019-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $661.31 | 2019-2025 | Calquence, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $513.82 | 2019-2025 | Opdivo, Krazati |
| Daiichi Sankyo INC. | $497.95 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $496.98 | 2019-2025 | Carvykti, Talvey, Darzalex |
| Lilly USA, LLC | $493.90 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $460.21 | 2019-2025 | Adcetris, Padcev, Tukysa |
| Astellas Pharma US INC | $372.68 | 2019-2025 | Xospata, Padcev, Vyloy |
| Eisai INC. | $355.75 | 2019-2025 | |
| Amgen INC. | $354.47 | 2019-2023 | Kyprolis, Blincyto, Nplate |
| Incyte Corporation | $331.31 | 2019-2025 | Monjuvi, Jakafi |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Revathi Angitapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.